Abstract <p>The intricacy of the manufacturing process, as well as the necessity of demonstrating Q1 (qualitative) and Q2 (quantitative) equivalence to the reference listed drug product, greatly impede the development of complex generics, particularly those intended for parenteral, ophthalmic, and otic use. Establishing the Q1 sameness of these excipients is complicated by several factors, such as lot-to-lot and source-to-source variations, the lack of compendial monographs or variations in compendial standards (if available), and the difficulty of purifying or analyzing and characterizing them.</p> Purpose <p>This article examines various challenges presented by the Q1 and Q2 sameness requirements to the development of complex parenteral, ophthalmic and otic generic products, as well as approaches and the steps that are being taken to overcome these challenges.</p> Methods <p>We explore a variety of initiatives that have been implemented by the industry and regulatory authorities to confront these challenges.</p> Results <p>Recently issued FDA guidance allows the waiver of the Q1 and Q2 sameness requirements for pH adjusters with an adequate justification. The Consolidated Appropriations Act clarifies for generic product manufacturers when inactive substances in an abbreviated new drug application are found to not meet the FDA’s Q1/Q2 sameness requirements. Moreover, several collaborative research, training, and resource exchange programs have been launched by the stakeholders to develop novel and innovative methodologies for characterizing complex excipients, as well as in vitro and in vivo testing procedures.</p> Conclusion <p>These initiatives will go a long way toward facilitating the development and market authorization of complex generics.</p>